CED Clinic: Personalized Cannabis Medicine

Clinicians should consider the route of administration when prescribing THC:CBD formulations, as bioavailability may vary significantly between methods.

Clinicians should be aware of the potential driving impairments associated with cannabis use and advise patients accordingly, especially in states where cannabis is legalized.

In this double-blind laboratory study, low-dose oral cannabidiol (50 mg) enhanced the acute analgesic properties of 4 mg hydromorphone without increasing negative subjective effects or adverse events, whereas higher CBD doses (200 mg) increased adverse effects.

Consider low-dose THC-CBD extracts as a potential adjunctive treatment for patients with Alzheimer's disease-associated dementia, while monitoring for safety and efficacy.

Consider dronabinol as a potential treatment option for managing agitation in Alzheimer's disease, especially in patients who have not responded well to traditional therapies.

Cannabis-induced acute pancreatitis should be considered in young patients presenting with acute abdominal pain and elevated pancreatic enzymes in the absence of gallstones or heavy alcohol use.

Integrative physicians should consider cannabis as a potential treatment for sleep disorders, while paying close attention to dosing to maximize benefits and minimize risks.

Consider the use of oral cannabinoids as a potential treatment option for patients with insomnia, while monitoring for individual responses and side effects.

In healthy men, acute administration of the cannabinoid receptor agonist nabilone enhanced peripheral insulin sensitivity while reducing fasting endocannabinoid levels, whereas the CB1 receptor antagonist CP-945,598 diminished insulin sensitivity in a dose-dependent manner.

This pilot study indicates that medicinal cannabis may be a feasible treatment option for adolescents with Tourette Syndrome, warranting further investigation in a fully powered trial.